[Clinical study on the permeability of FT-207 and 5-FU in primary lung cancer]. 1985

R Aogauchi, and N Tsubota, and C Yamashita, and K Yoshikawa, and N Ishii, and K Nakamura

Distribution of the FT-207 and 5-FU between plasma and lung tissue as well as tumor tissue was studied in 28 patients with lung cancer after administration of FT-207 preoperatively. Two methods of administration were employed, one is intravenous drip infusion (IV Group) (800 mg/day for three days) and the other is suppository (Supp Group) (750 mg 2/day for three days). The level of FT-207 was higher in plasma than in normal lung tissue or tumor tissue in IV Group. There was no difference in the level of FT-207 between plasma, normal lung tissue and tumor tissue in Supp Group. The level of 5-FU was higher in tumor tissue than in plasma both in IV Group and Supp Group. Furthermore, intravenous drip infusion was more effective method to give FT-207 because of higher level of 5-FU in tumor tissue than in normal tissue. Comparison of the tissue level in IV Group between two histologic types of tumor, i.e. squamous cell carcinoma and adenocarcinoma, disclosed that there was no significant difference in the concentration of FT-207 and 5-FU both in normal lung tissue and in tumor tissue.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010539 Permeability Property of membranes and other structures to permit passage of light, heat, gases, liquids, metabolites, and mineral ions. Permeabilities
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002463 Cell Membrane Permeability A quality of cell membranes which permits the passage of solvents and solutes into and out of cells. Permeability, Cell Membrane
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

R Aogauchi, and N Tsubota, and C Yamashita, and K Yoshikawa, and N Ishii, and K Nakamura
August 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
R Aogauchi, and N Tsubota, and C Yamashita, and K Yoshikawa, and N Ishii, and K Nakamura
June 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
R Aogauchi, and N Tsubota, and C Yamashita, and K Yoshikawa, and N Ishii, and K Nakamura
September 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
R Aogauchi, and N Tsubota, and C Yamashita, and K Yoshikawa, and N Ishii, and K Nakamura
October 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
R Aogauchi, and N Tsubota, and C Yamashita, and K Yoshikawa, and N Ishii, and K Nakamura
April 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
R Aogauchi, and N Tsubota, and C Yamashita, and K Yoshikawa, and N Ishii, and K Nakamura
April 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
R Aogauchi, and N Tsubota, and C Yamashita, and K Yoshikawa, and N Ishii, and K Nakamura
July 1985, Hinyokika kiyo. Acta urologica Japonica,
R Aogauchi, and N Tsubota, and C Yamashita, and K Yoshikawa, and N Ishii, and K Nakamura
July 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
R Aogauchi, and N Tsubota, and C Yamashita, and K Yoshikawa, and N Ishii, and K Nakamura
May 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
R Aogauchi, and N Tsubota, and C Yamashita, and K Yoshikawa, and N Ishii, and K Nakamura
December 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!